Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B NXLmbHdxSXCxcITvd4l{KEG|c3H5 NX;XSnFSOeLCk{ZCpO69VQ>? NWKxZpIxPDhiaB?= NWXVS5VOcW6qaXLpeJMh[2WubDDndo94fGh? MW[yOlMzQTZyOB?=
PLC/PRF/5  MmrORZBweHSxc3nzJGF{e2G7 M{W3XlHjiJN3wrFOwG0> NX;RZlFGPDhiaB?= NFLHZ2pqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MnLTNlY{Ojl4MEi=
HepG2  NF\TdlZCeG:ydH;zbZMhSXO|YYm= Ml2wNgKBmzYEoN88US=> MVW0PEBp MVzpcohq[mm2czDj[YxtKGe{b4f0bC=> NGTP[Y0zPjN{OU[wPC=>
HEK293 M1PZRmZ2dmO2aX;uJGF{e2G7 NXzIVlQ1OC534pEJ{txO M{D6TVIwPC94IHi= Mnv6doVlfWOnczDHVnA4QCCneIDy[ZN{cW:w MmHDNlU5PThyM{K=
GEO MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHqzTpoxNjBzLUKwJO69VQ>? MoTJPVYhcA>? M4XFSmROW09? MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYKyOVg{QDN7MR?=
SW48 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzv[2ozOC5yMT2yNEDPxE1? MV65OkBp MojYSG1UVw>? NGTZSFVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NV;zPG8zOjV6M{izPVE>
HT29 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGwMlAyNTJyIN88US=> MWq5OkBp M2nZOGROW09? MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVHSbollOjV6M{izPVE>
SW480 NFftPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmwMlAyNTJyIN88US=> M3PXRlk3KGh? NIqxSnFFVVOR MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVvwS4pSOjV6M{izPVE>
SW620 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rHXFAvODFvMkCg{txO M{WyNlk3KGh? MX7EUXNQ NV7PZ205cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYKyOVg{QDN7MR?=
HCT116 NGjNb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2wMlAyNTJyIN88US=> MkDhPVYhcA>? NYnTXoZLTE2VTx?= Mny1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnTnNlU5Ozh|OUG=
LOVO M1T3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fVc|AvODFvMkCg{txO M2P2SFk3KGh? M4GwN2ROW09? M{nYWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmDiNlU5Ozh|OUG=
HCT150 NWH2O2xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MViwMlAyNTJyIN88US=> NU\wN2NXQTZiaB?= MVXEUXNQ M1\NUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYKyOVg{QDN7MR?=
SW48-CR NYnBUnROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGwMlAyNTJyIN88US=> MXu5OkBp MljOSG1UVw>? MoLwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGD0cIIzPTh|OEO5NS=>
GEO-CR Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPjbYU6OC5yMT2yNEDPxE1? NFHDeIw6PiCq NYjMWmFyTE2VTx?= NYfPc2lMcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Ml7BNlU5Ozh|OUG=
KB-31 MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXjWo92UUN3ME21MlXDuTBwMzDuUS=> NX\UcIJQOjV5NUOzOlE>
KB-G2 MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF75Z2FKSzVyPUmuNeKyOC5zIH7N MYWyOVc2OzN4MR?=
LLC-PK1 M2DYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTR{LkFCtVMvOiCwTR?= NVXZVHRDOjV5NUOzOlE>
LLC-PK1/MRP2 NUG0WnB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLTb5VKSzVyPUiyMlTDuTJwNzDuUS=> NFjUTFIzPTd3M{O2NS=>
HEK293 NYHrVGw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3ifVRKSzVyPUGxMlDDuTFwMjDuUS=> NYXSSml[OjV5NUOzOlE>
HEK293/OATP1B1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfkUpRNUUN3ME22MlLDuTBwMzDuUS=> MUWyOVc2OzN4MR?=
HROC18 NFHpeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DmZ2lEPTB;MT6zJO69VQ>? NFO1[oIzPTNyOUmxOC=>
HROC24 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPBTWM2OD12Lk[g{txO M{P2XlI2OzB7OUG0
HROC43 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjGTnBKSzVyPUWuN{DPxE1? MnjlNlU{ODl7MUS=
HROC46 NXn3b4UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLrTWM2OD1{LkSg{txO Mn;qNlU{ODl7MUS=
RJ345 MkjhSpVv[3Srb36gRZN{[Xl? MnWwNE42NzVizszN NHX1d4wzPCCq NFTKU2NFVVOR NXfMbZh[cW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v MU[yOVI2Ozl7NB?=
RJ348 NXvQSYQ4TnWwY4Tpc44hSXO|YYm= NWLRUVR2OC53L{Wg{txO NFrWZlczPCCq NELuWVJFVVOR Ml7JbY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u MkizNlUzPTN7OUS=
MCF-7 NXrp[IxuTnWwY4Tpc44hSXO|YYm= NWHMZ3ROOC53L{Wg{txO NX\QO2VYOjRiaB?= M2\zXWROW09? NVXhNZVlcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v MoPONlUzPTN7OUS=
MDA-MB-231 MVnGeY5kfGmxbjDBd5NigQ>? MXiwMlUwPSEQvF2= NHPqV5IzPCCq M3;FT2ROW09? NHfUbYxqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> NXrI[WpbOjV{NUO5PVQ>
HT15 NWXxbnNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Hvd|EuOjBizszN MmnHOFghcA>? MYnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NH;iXZIzPTB5MUCxPC=>
DLD1 NXzjdXFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf5NU0zOCEQvF2= MXK0PEBp MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWGyOVA4OTBzOB?=
HT-29 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWxMVIxKM7:TR?= NWDSWXFLPDhiaB?= NGLIc3NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHTmc4MzPTB5MUCxPC=>
Hct-116 M2P2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmqzNU0zOCEQvF2= MkDZOFghcA>? NXz2UpB2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYTid29COjVyN{GwNVg>
HT15 M3K5O2Fxd3C2b4Ppd{BCe3OjeR?= NGnyfJoyNTFyIN88US=> MVO0PEBp MVjpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NV3sdHhvOjVyN{GwNVg>
DLD1 NIHMVHZCeG:ydH;zbZMhSXO|YYm= M3u2dlEuOTBizszN NUnPW5ZNPDhiaB?= NIj2OYlqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3HmT|I2ODdzMEG4
HT-29 NFK1WmRCeG:ydH;zbZMhSXO|YYm= MoP2NU0yOCEQvF2= NXTz[JRkPDhiaB?= MYLpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NImwSHIzPTB5MUCxPC=>
Hct-116 NVrN[GpWSXCxcITvd4l{KEG|c3H5 NHnUTlAyNTFyIN88US=> M2jQWVQ5KGh? NYPGWHMxcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1K0W|I2ODdzMEG4
GBM5 NF\RXHVCeG:ydH;zbZMhSXO|YYm= M1\PRVAvPeLCk{GuNQKBkc7:TR?= M{HQOVI1KGh? NF;XbWZFVVOR M3\H[olvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> M2D4clI1QTFzMkG1
GBM6 MXLBdI9xfG:|aYOgRZN{[Xl? MXSwMlXjiJNzLkFihKnPxE1? NWDPb21MOjRiaB?= NEHZOGtFVVOR NFWyO|NqdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> NITKfIozPDlzMUKxOS=>
GBM12 NFX2b25CeG:ydH;zbZMhSXO|YYm= NVjVdppROC534pETNU4x6oDLzszN MUOyOEBp MorDSG1UVw>? MYrpcpRmemGldIOge4l1cCCuYYDheIlvcWJidH:gbY5lfWOnIHPlcIwh\GWjdHi= MnL6NlQ6OTF{MUW=
GBM14  NHf1SZpCeG:ydH;zbZMhSXO|YYm= M3\Xe|AvPeLCk{GuNQKBkc7:TR?= MoLoNlQhcA>? MonaSG1UVw>? M3TiWYlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> NFXyVlgzPDlzMUKxOS=>
Hep3B Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnoeYo4OeLCk{KuOeKh|ryP MmfsNlQwPDhxN{KgbC=> MoHmbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M2[yUlI1QDh3OEmw
PLC/PRF/5  MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTRNgKBmzJwNdMg{txO NFW2dYkzPC92OD:3NkBp M{nSOolvcGmkaYTzJINmdGxiZ4Lve5Rp MViyOFg5PTh7MB?=
HepG2  M1zRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[0bmwy6oDVMj61xsDPxE1? M1[4W|I1NzR6L{eyJIg> M3WyeYlvcGmkaYTzJINmdGxiZ4Lve5Rp MVeyOFg5PTh7MB?=
HCT116  MWXGeY5kfGmxbjDBd5NigQ>? MoTpNVAwOjBxNECg{txO MU[yOEBp MVjpcoR2[2W|IGDVUWEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NULDfI9TOjR5NkO2NVE>
Lim2405 M{DkdWZ2dmO2aX;uJGF{e2G7 NFzvNJA1OCEQvF2= Ml3JNlQhcA>? M1XKPYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? MmPWNlQ4PjN4MUG=
LoVo MWjGeY5kfGmxbjDBd5NigQ>? NGP5XIQ1OCEQvF2= M4L6TVI1KGh? NF\yVVhqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NYnNb4pCOjR5NkO2NVE>
Lim1215 NIG3SVhHfW6ldHnvckBCe3OjeR?= M4\DRlQxKM7:TR?= MVGyOEBp NWG3UVZDcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NFTROo0zPDd4M{[xNS=>
SW48 NV\DTGc1TnWwY4Tpc44hSXO|YYm= NHL6N|M1OCEQvF2= NWD2eJI6OjRiaB?= Mkj1bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MY[yOFc3OzZzMR?=
RKO  MkTiSpVv[3Srb36gRZN{[Xl? NHv5T2w1OCEQvF2= MnTBNlQhcA>? MofFbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NYTpNHRbOjR5NkO2NVE>
SW837 MmjUSpVv[3Srb36gRZN{[Xl? Ml62OFAh|ryP NVrnUpJ7OjRiaB?= M1Kxfolv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M1H1O|I1PzZ|NkGx
SW1463 MYLGeY5kfGmxbjDBd5NigQ>? M{nJSlQxKM7:TR?= MkX6NlQhcA>? M2\ITIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? MXmyOFc3OzZzMR?=
SW480 NFnDfndHfW6ldHnvckBCe3OjeR?= MWm0NEDPxE1? NFLOUIQzPCCq MUDpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MojINlQ4PjN4MUG=
Vaco432 NVPKUG5mTnWwY4Tpc44hSXO|YYm= NFns[|M1OCEQvF2= M4ridFI1KGh? NWnUeYNqcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MYiyOFc3OzZzMR?=
Vaco400 NW\GdZNZTnWwY4Tpc44hSXO|YYm= NX73b|FMPDBizszN M4jCU|I1KGh? M4TLbIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? MkXlNlQ4PjN4MUG=
DLD1 MYnGeY5kfGmxbjDBd5NigQ>? MXO0NEDPxE1? Mlz5NlQhcA>? MkTUbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MYeyOFc3OzZzMR?=
HT29  M1\vZWZ2dmO2aX;uJGF{e2G7 M3jGZ|QxKM7:TR?= MYGyOEBp MULpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NUHDTJEzOjR5NkO2NVE>
PLC/PRF/5  NFPtfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;MNgKBmzYEtV2= NV\PTpB5OjRxNEivO|IhcA>? MUjpcohq[mm2czDj[YxtKGe{b4f0bC=> MojmNlMyPjlzNEi=
HepG2 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe1cFNROeLCk{ZCuW0> Ml;xNlQwPDhxN{KgbC=> MXHpcohq[mm2czDj[YxtKGe{b4f0bC=> Ml;3NlMyPjlzNEi=
Hep3B  MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfsZ5U{OeLCk{ZCuW0> NETWWngzPC92OD:3NkBp M{HSOYlvcGmkaYTzJINmdGxiZ4Lve5Rp MWmyN|E3QTF2OB?=

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
in solvent
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02835924 Not yet recruiting Metastatic Colorectal Cancer Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Bayer July 2016 Phase 2
NCT02795156 Not yet recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer July 2016 Phase 2
NCT02664077 Recruiting Stage III (IIIB or IIIC) Colon Cancer NSABP Foundation Inc|Bayer June 2016 Phase 3
NCT02383433 Recruiting Metastatic Pancreatic Adenocarcinoma Case Comprehensive Cancer Center|National Cancer Institute (NCI) June 2016 Phase 2
NCT02773524 Not yet recruiting Gastro-Oesophageal Cancer Australasian Gastro-Intestinal Trials Group|Canadian Cancer Trials Group June 2016 Phase 3
NCT02788279 Recruiting Colorectal Cancer Hoffmann-La Roche June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID